Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
152
resultados
Última actualización
13/09/2026 [07:28:00]
Resumen de: CN122245701A
The invention provides an inflammatory bowel disease subtype diagnosis model and a construction method thereof, and the diagnosis model is characterized in that an RNA editing characteristic spectrum capable of specifically distinguishing Crohn's disease and ulcerative colitis is extracted from a PBMC sample obtained by minimally invasive acquisition through a set of innovative bioinformatics flow, and the RNA editing characteristic spectrum is used for constructing the inflammatory bowel disease subtype diagnosis model. And a machine learning model is constructed and trained by using the characteristic spectrum, and finally accurate and automatic diagnosis of the IBD subtype is realized.
Resumen de: WO2026128869A1
Personalized methods of determining a reference PDE4 Inhibitor Resistance Metric for treating a future patient in need of treatment, and methods of treating a subject with an inflammatory bowel disease are provided.
Resumen de: CN122218255A
The invention discloses a combined marker for detecting Crohn's disease and application of the combined marker, and relates to the technical field of biology and medicine. The combined marker is prepared from the following components: chenodeoxycholic acid, lithocholic acid, ursodeoxycholic acid, glycochenodeoxycholic acid, glycolithocholic acid, glycoursodeoxycholic acid, taurochenodeoxycholic acid, taurocholic acid, taurocholic acid, tauroursodeoxycholic acid, cholic acid, glycocholic acid, taurocholic acid, glycodeoxycholic acid and taurodeoxycholic acid. Adding glycylcholic acid sulfate and isolithocholic acid; the combined marker can be used for clinical diagnosis or monitoring of Crohn's disease. The metabonomics combined marker for Crohn disease diagnosis is explored, a diagnosis and identification method which is simple and convenient to detect, low in cost and easy to accept by patients is created, a traditional diagnosis mode can be well replaced, and the metabonomics combined marker has great significance in clinical diagnosis and treatment of Crohn diseases and has popularization value.
Resumen de: US20260159887A1
0000 Inflammatory bowel disease (IBD) in humans and dogs and other companion animals is characterized by infiltration of lymphocytes and macrophages into the mucosa and submucosa and clinical signs of gastrointestinal (GI) dysfunction (diarrhea, malabsorption, weight loss). Alteration of the gut environment and development of dysbiosis may allow the overgrowth of pathogenic bacteria and induction of intestinal injury and inflammation in IBD. What is needed are novel methods that allow for rapid diagnosis of IBD (and follow-up monitoring) and treatment of the disease. The present disclosure relates to methods for diagnosing and treating inflammatory bowel disease (IBD) or gastrointestinal lymphoma.
Resumen de: AU2024402123A1
Aspects of the disclosure provides composition and methods for treating a subject having inflammatory bowel disease, the method comprising administering to the subject a hemojuvelin (HIV) antagonist (e.g., anti-HJV antibody).
Resumen de: CN122150473A
The invention relates to the technical field of quality standard detection of traditional Chinese medicine preparations, in particular to a quality detection method of food retention removing and bowel relaxing capsules. According to the method for determining the characteristic chromatogram of the capsule for removing food retention and relaxing bowels, high performance liquid chromatography is adopted for determination, octadecylsilane chemically bonded silica is used as a filler, the column length is 250 mm, the inner diameter is 4.6 mm, and the particle size is 5 mu m. Acetonitrile is used as a mobile phase A, and a 0.2% phosphoric acid solution is used as a mobile phase B for elution; the flow rate is 1.0 ml per minute; the column temperature is 40 DEG C; and the detection wavelength is 265 nm. The method has the advantages of good specificity, good sample injection precision, good repeatability and good intermediate precision, and a test solution is stable at room temperature within 48 hours.
Resumen de: CN122140776A
The invention relates to a composition for preventing or treating inflammatory bowel diseases and application thereof, belongs to the technical field of inflammatory bowel diseases, and solves the problems that in the prior art, pathogenesis of intestinal symbiotic fungi mediated inflammatory bowel diseases is unclearly explained, and a treatment means for targeting fungi related signal channels is lacked. An inflammatory bowel disease intervention scheme based on flora interaction does not exist; existing therapeutic drugs are difficult to regulate and control the immune homeostasis of intestinal tracts, amplify regulatory T cells and the like. The invention provides a composition for preventing or treating inflammatory bowel disease and application thereof, the composition comprises at least one of a Dectin-2/CARD9 antagonistic antibody or small molecule inhibitor, an antifungal agent, a lactobacillus johnsonii WXY strain and/or L-glutamic acid, and the preservation number is CGMCC No.37794. According to the present invention, the colitis can be exacerbated through the Dectin-2-CARD9 pathway, the proliferation of the regulatory T cells mediated by Lactobacillus johnsonii and L-glutamic acid can be inhibited, the change of the marker composition in the inflammatory bowel disease patients can be verified, and the diagnostic marker and the potential treatment target can be provided for the inflammatory bowel disease.
Resumen de: CN122158089A
The invention discloses an out-of-hospital grading diagnosis method based on IBS disease, and relates to the technical field of medical diagnosis, and the method comprises the following steps: S1, obtaining multi-dimensional information related to IBS disease provided by a patient in an out-of-hospital scene; s2, performing standardized preprocessing on the out-of-hospital multi-dimensional information to obtain feature data which can be input into an algorithm model; and S3, inputting the standardized feature data into a preset IBS grading diagnosis algorithm model, and outputting an IBS disease grading diagnosis result of the patient. According to the out-of-hospital grading diagnosis method based on the IBS disease, multi-dimensional out-of-hospital information is integrated, standardized preprocessing is combined to eliminate data errors, multi-feature screening and model optimization are adopted, a Roman IV diagnosis standard is referred to to train a model, meanwhile, diagnosis reliability is judged through confidence, and the misdiagnosis rate and the missed diagnosis rate are reduced; and a model iteration updating mechanism can continuously improve the diagnosis precision and adapt to the change of clinical requirements.
Resumen de: CN122145556A
The invention discloses a granzyme B targeting complex, a radiopharmaceutical and an imaging application of the granzyme B targeting complex in intestinal immune abnormal activity, and belongs to the field of nuclear medicine diagnosis and treatment. The complex is subjected to covalent modification, the recognition peptide and granzyme B are subjected to specific non-covalent binding firstly, then irreversible covalent linkage is triggered by means of the proximity effect, and the technical bottlenecks that an existing granzyme B probe is low in target tissue intake, short in-vivo residence time and narrow in imaging window are effectively solved. The selective retention capacity and the imaging specificity of the probe at a target part are obviously improved. The complex and the radiopharmaceutical disclosed by the invention can specifically target granzyme B released by abnormal immune activity of an intestinal diseased region, realize intestinal inflammations such as Crohn's disease and ulcerative colitis and noninvasive, dynamic and quantitative nuclear medicine imaging of aGVHD, can accurately evaluate the abnormal immune activity of the intestinal tract and monitor the treatment effect, and have good application prospects. A core tool is provided for early diagnosis and precise diagnosis and treatment of the diseases, and the kit has important clinical transformation value and application prospect.
Resumen de: US20260152808A1
The present invention relates to a score (TOPOSCORE) for describing eubiosis or dysbiosis in an individual, that can be used, inter alia, for determining if a patient is likely to respond to an immune-oncology treatment, more precisely, a treatment comprising administration of an immune checkpoint inhibitor (ICI). The TOPOSCORE represents a robust biomarker predicting immunosensitivity and immunoresistance to ICI on an individual basis.
Resumen de: WO2026115801A1
Provided is an inflammatory bowel disease testing method. This inflammatory bowel disease testing method comprises (1) a step for detecting biomarkers in a biological sample collected from a subject. The biomarkers include: proHp and LRG; or proHp and CRP.
Resumen de: WO2026115199A1
The present invention is related to a method for determining or confirming inflammatory bowel disease (IBD) in a subject, the method comprising detecting the amount of keratin 18 (K18) and/or keratin 19 (K19) mRNA or protein in a biological sample obtained from said subject. The present method can also be used for differentiating microscopic colitis from IBD.
Resumen de: US20260153518A1
0000 A method for detecting an immune-mediated inflammatory disease characterized by an increase in expression of MMP12, in a subject, a diagnostic drug containing a substance that specifically interacts with MMP12, and a therapeutic agent containing an MMP12 inhibitory substance.
Resumen de: CN122135993A
The invention relates to the technical field of ulcerative colitis prediction, in particular to an ulcerative colitis prediction model, a construction method and a prediction kit. The risk score of each sample is equal to 68.798 to 11.031 * relative expression quantity of HMGCS2, 46.586 * relative expression quantity of GCNT2, 20.391 * relative expression quantity of B4GALNT2, 5.719 * relative expression quantity of NAT8B, 26.562 * relative expression quantity of LPCAT1, 17.042 * relative expression quantity of PPARGC1A, 10.500 * relative expression quantity of ACSS2, 3.110 * relative expression quantity of PDK2, and 77.421 * relative expression quantity of HADHA. A risk score less than zero is defined as non-ulcerative colitis, and a risk score greater than zero is defined as ulcerative colitis. The invention provides the ulcerative colitis diagnosis model, the model can be suitable for rapid diagnosis of clinical samples, an objective and quantitative judgment basis is provided for UC diagnosis, and the problem that a traditional diagnosis method is insufficient in sensitivity and specificity is solved.
Resumen de: CN118581207A
The invention provides a marker for diagnosing systemic inflammation and application, the marker comprises ADGRE3mRNA or ADGRE3 protein, or ADGRE3mRNA fragment and ADGRE3 protein fragment, the marker content in samples of systemic inflammation patients and healthy people has significant difference, clinical verification shows that the marker is high in diagnosis sensitivity and specificity, and the marker can be applied to diagnosis of systemic inflammation. Therefore, systemic inflammation can be accurately diagnosed by detecting the transcription level of ADGRE3 mRNA or the expression level of ADGRE3 protein in an individual sample. Compared with an existing inflammation marker, the ADGRE3 mRNA and the ADGRE3 protein have higher sensitivity and specificity in the aspect of diagnosis of systemic inflammation.
Resumen de: US20260146996A1
Provided is an examination method for irAE enteritis, said examination method comprising a detection step for detecting, as an indicator of ulcerous colitis-like irAE enteritis, an antibody that immunologically reacts with a fragment of, or the entirety of, integrin ανβ6 in a specimen.
Resumen de: CN122075500A
The invention discloses application of a hyocholic acid bile acid component in preparation of a medicine for treating irritable bowel syndrome. The research finds that the content of hyocholic acid components in peripheral excrement of an IBS-D patient treated by the traditional Chinese medicine is obviously increased. Moreover, the hyocholic bile acid component is significantly reduced in the peripheral fecal sample of the IBS-D patient as compared to the health control group. The further research finds that hyodeoxycholic acid and natural traditional Chinese medicine pulvis fellis suis can reduce the peripheral serotonin level by inhibiting the activity of tryptophan hydroxylase 1, and the symptoms of diarrhea and stomachache of mice induced by TNBS are remarkably improved. The application value of the hyocholic acid bile acid component in treatment of IBS-D. The invention provides the application value of the hyocholic acid bile acid component.
Resumen de: WO2016167365A1
Provided is a marker for determining a mental disease, which can be used for an objective diagnosis of a mental disease. A marker for determining a metal disease, which comprises at least one enterobacterium selected from those belonging to Bifidobacterium, Lactobacillus, Lactobacillus brevis, Lactobacillus reuteri subgroup, Lactobacillus sakei subgroup, Atopobium cluster, Bacteroides fragilis group, Enterococcus, Clostridium coccoides group, Clostridium leptum subgroup, Staphylococcus, Clostridium perfringens and Enterobacteriaceae.
Resumen de: US20260140112A1
Provided herein is a peptide array comprising a plurality of flagellin peptides corresponding to highly conserved peptide regions. For example, the peptide array comprises a plurality of Lachnospiraceae flagellin peptides, which can be selected from a hinge region of Lachnospiraceae flagellin. Also provided is antibody of fragment thereof that binds to one or more of the plurality of the flagellin peptides in the peptide array. The peptide array and antibody are useful in determining an immunosignature from a biological sample from a subject. The immunosignature is useful in diagnosis of an immune-mediated disease, in monitoring progression of an immune-mediated disease, in identifying subjects susceptible to certain treatments, and in monitoring treatment response.
Resumen de: US20260142011A1
Provided herein are systems and methods for optimizing a biological therapy regimen for a subject. The subject may be a patient diagnosed with an immune mediated inflammatory disease. In some embodiments, the systems and methods may involve inputting patient data into a model to forecast a drug concentration level in a patient and establish a dosing regimen for maintaining a pre-specified threshold drug concentration level in the patient. The pre-specified threshold may be a target concentration level for effective treatment of the immune mediated inflammatory disease in the patient.
Resumen de: EP4745571A1
0001 A method for determining a mucosal disorder in a gastrointestinal tract includes: a preparation step for preparing a biological sample collected from a subject to which an endoscopic dye compound has been administered; a measurement step for measuring an amount of the endoscopic dye compound or a metabolite thereof in the biological sample; a comparison step for comparing the measured amount of the endoscopic dye compound or a metabolite thereof with a reference value; and a determination step for determining that the subject is highly likely to have a mucosal disorder in the gastrointestinal tract if the measured amount of the endoscopic dye compound or a metabolite thereof is equal to or greater than the reference value.
Resumen de: EP4744731A2
0001 The present invention relates to an antibody for treating or preventing autoimmune diseases. The antibody of the present invention comprises a heavy chain variable region set forth in SEQ ID NO: 1 and a light chain variable region set forth in SEQ ID NO: 6.
Resumen de: CN122060665A
The invention relates to the technical field of cell biology, in particular to a construction method of children Crohn's disease intestinal tract organoid. According to the invention, a natural immune microenvironment is established by using intestinal tissues from children patients suffering from Crohn's disease and immune cells residing in the tissues, so that the experimental limitation of insufficient peripheral blood volume of children is avoided; p-nitro branstatin is innovatively introduced into a culture system, so that the formation of organoid is effectively increased. Compared with the traditional inhibitor blebbistatin of NMII, the p-nitro branstatin has the advantages that the defects of poor solubility and poor light stability are avoided, the composition stability of the culture medium is favorably maintained, and the p-nitro branstatin is more suitable for a system which is a gas-liquid type organ and is longer in liquid change interval and needs to be cultured for a long time. The invention provides a new model for exploration of related mechanisms of children Crohn's disease and evaluation of drug efficacy.
Resumen de: CN122056348A
The invention discloses application of rice bran in preparation of food or health care products with functions of relaxing bowels and promoting intestinal peristalsis, and relates to the field of functional food. According to the application, the combination of active components of unsaturated fatty acid-phenolic acid-amino acid derivatives in the rice bran is defined through systematic component analysis, richer material basis explanation is provided for the bowel relaxing effect of the rice bran, the effective concentration range and the optimal concentration of the rice bran are quantified, and a direct experimental basis is provided for product dosage design.
Nº publicación: CN122042980A 15/05/2026
Solicitante:
SICHUAN PROVINCIAL PEOPLES HOSPITAL SICHUAN ACAD OF MEDICAL SCIENCES
\u56DB\u5DDD\u7701\u533B\u5B66\u79D1\u5B66\u9662\u00B7\u56DB\u5DDD\u7701\u4EBA\u6C11\u533B\u9662
Resumen de: CN122042980A
The invention discloses application of retin-1 in prediction of an intestinal lesion range of ulcerative colitis, and relates to the technical field of inflammatory bowel disease markers. The serum Omentin-1 level can accurately predict the intestinal lesion range of the UC patient in the active period. Therefore, the invention provides a new means for managing the dynamic change of the disease of the UC patient clinically, and has a better clinical application prospect.
BOPI
Sede Electrónica
